---
title: "Cloudbreak Pharma Secures Withdrawal of Arbitration in Cedar Wealth Dispute"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274154481.md"
description: "Cloudbreak Pharma, Inc. announced that the Shanwei Arbitration Commission has approved Cedar Wealth’s request to withdraw arbitration proceedings against the company and its subsidiary, Cloudbreak Guangzhou, following a settlement agreement. Cedar Wealth will cover the arbitration fees, which helps reduce legal uncertainties for Cloudbreak’s shareholders and potential investors. The company will provide further updates as the settlement progresses. Cloudbreak Pharma is a pharmaceutical firm listed on the Hong Kong Stock Exchange, focusing on drug development and healthcare activities in Hong Kong and mainland China."
datetime: "2026-01-29T12:42:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274154481.md)
  - [en](https://longbridge.com/en/news/274154481.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274154481.md)
---

# Cloudbreak Pharma Secures Withdrawal of Arbitration in Cedar Wealth Dispute

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Cloudbreak Pharma, Inc. ( (HK:2592) ) has issued an update.

Cloudbreak Pharma Inc. announced that the Shanwei Arbitration Commission has approved Cedar Wealth’s application to withdraw arbitration proceedings against the company and its subsidiary Cloudbreak Guangzhou, following the parties’ earlier settlement agreement. Under the decision, Cedar Wealth will bear the arbitration fees, marking a key step toward resolving the dispute and reducing legal uncertainties for Cloudbreak’s shareholders and potential investors, although the company indicated it will issue further updates as the wider proceedings and settlement continue to progress.

**More about Cloudbreak Pharma, Inc.**

Cloudbreak Pharma Inc. is a pharmaceutical company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, operating through its subsidiaries including Cloudbreak Guangzhou. The group is engaged in drug development and related healthcare activities, targeting markets accessible via its Hong Kong listing and mainland China operations.

**Average Trading Volume:** 2,700,113

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$2.16B

### Related Stocks

- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [02592.HK](https://longbridge.com/en/quote/02592.HK.md)

## Related News & Research

- [20:00 ETLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma](https://longbridge.com/en/news/286687690.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [09:13 ETThe new Neurology-First Platform to Accelerate Clinical Trial Recruitment, Real-World Evidence, and Therapy Adoption](https://longbridge.com/en/news/286919710.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)